Ocular Manifestations in Rheumatic Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03753893|
Recruitment Status : Active, not recruiting
First Posted : November 27, 2018
Last Update Posted : November 27, 2018
|Condition or disease||Intervention/treatment|
|Uveitis Conjunctivitis Keratoconjunctivitis Sicca Xerophthalmia Eye Hemorrhage Optic Neuritis Papilledema Orbital Diseases Retinal Vein Occlusion Retinal Artery Occlusion Macular Edema Retinitis Chorioretinitis Iridocyclitis Scleritis Choroid Hemorrhage Blindness Amaurosis Fugax||Other: No intervention used|
For the purposes of determining the prevalence of ocular complications in inflammatory rheumatic diseases, the following search terms were used: conjunctivitis, keratoconjunctivitis sicca, xerophthalmia, uveitis, eye hemorrhage, optic neuritis, papilledema, orbital disease, retinal artery/vein occlusion, macular edema, retinitis, chorioretinitis, scleritis, iridocyclitis, choroid hemorrhage, blindness and amaurosis fugax.
These terms were searched in the context of a corresponding inflammatory disease on Medline, Cochrane and Web of Science from their inception (1966, 1991 and 1990 respectively) until the point of study completion.
Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in an inflammatory rheumatic disease. Studies were excluded if they were review articles, case reports where all patients experienced the same ocular comorbidity, if different comorbidities were not grouped independently, and if the study reported on fewer than 20 patients. When the same study cohort was used in more than one analysis, the most recent or largest sample-size study was included. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used to assess the quality of cohort, case-control, and cross-sectional studies.
|Study Type :||Observational|
|Estimated Enrollment :||1 participants|
|Observational Model:||Ecologic or Community|
|Official Title:||Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases|
|Actual Study Start Date :||May 1, 2013|
|Estimated Primary Completion Date :||October 1, 2019|
|Estimated Study Completion Date :||October 1, 2019|
- Other: No intervention used
no intervention used
- Prevalence of ocular manifestations of inflammatory rheumatic diseases [ Time Frame: data is collected once per year up to 2020 ]Prevalence of ocular manifestations of inflammatory rheumatic diseases
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03753893
|Principal Investigator:||Janet Pope, MD||Lawson Health Research Institute|